S-5004-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Tina Smith (D-MN)
What it does
This bill would amend the Employee Retirement Income Security Act of 1974 (ERISA) to require employer-sponsored group health plans to apply cost-sharing terms for oral anticancer drugs (pills, capsules, etc.) that are no less favorable than those applied to anticancer drugs administered intravenously or by injection in a clinical setting. It would prohibit plans from responding to this requirement by raising costs or restricting benefits for any anticancer medications. It also directs the Government Accountability Office to study the law's impact on patient out-of-pocket costs within two years of enactment.
Who benefits
Cancer patients enrolled in employer-sponsored group health plans who are prescribed oral anticancer medications — currently often subject to higher cost-sharing under pharmacy ("specialty drug") benefit tiers than infused drugs covered under medical benefits. Patients with cancers commonly treated with oral therapies (e.g., certain leukemias, lung cancers, breast cancers). Oncologists and prescribers who would face fewer financial barriers when recommending oral therapies. Oral anticancer drug manufacturers, whose products may become more accessible to patients. Caregivers and family members of cancer patients who may face reduced financial strain.
Who is hurt
Employers and insurers who sponsor group health plans and would bear the cost of equalizing benefits, potentially passing costs on through higher premiums for all enrollees. Workers and families enrolled in group plans who do not have cancer but may see modest premium increases. Pharmacy benefit managers (PBMs) whose specialty drug tier structures would be constrained. Infusion centers and outpatient clinical facilities that administer IV cancer drugs, which could see reduced patient volume if oral therapies become more financially accessible. The bill does not apply to individual market plans or Medicare/Medicaid, so patients in those programs would not benefit.
Supporters argue
Supporters argue that the current two-tier system creates an arbitrary financial penalty for patients whose cancer happens to be best treated with an oral drug rather than an infused one — a distinction driven by insurance benefit design, not medical need. They contend that oral anticancer drugs are often placed in the highest specialty drug tiers, exposing patients to thousands of dollars in annual out-of-pocket costs, while the same or equivalent infused drugs are covered under medical benefits with far lower cost-sharing. Studies have shown that high out-of-pocket costs cause cancer patients to delay or abandon treatment, worsening outcomes. The bill's anti-circumvention provision and GAO study requirement add meaningful accountability.
Opponents argue
Opponents argue that mandating benefit parity across drug delivery methods removes a key cost-management tool from insurers and employers, and that the resulting cost increases would be spread across all enrollees through higher premiums — effectively taxing the healthy to subsidize a specific patient population. They contend that prior authorization and utilization management — which the bill explicitly preserves — are insufficient guardrails, and that equalizing cost-sharing for high-cost specialty oral drugs could accelerate overall premium growth. Critics may also argue the bill addresses only ERISA-governed plans, leaving a fragmented patchwork where individual market and public program enrollees receive no benefit, undermining the case for a federal rather than comprehensive solution.